Drugmaker Valeant CEO leaving as investor Ackman joins board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Wall Street ends higher as tech rebounds before Nvidia results
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
- Dick's Sporting Goods (DKS) Misses Q2 EPS by 25c, Offers Guidance
Valeant (VRX) is Not Investable - Piper Jaffray
March 21, 2016 11:34 AM EDTPiper Jaffray analyst David Amsellem weighed in on Valeant Pharmaceuticals (NYSE: VRX) after the company announced this morning that CEO Michael Pearson will be stepping down, and that William Ackman will be joining the Board of Directors. More importantly, the company cited the... More
Valeant Pharma (VRX) Gives Up Gains; Trades Flat
March 21, 2016 9:43 AM EDTValeant Pharma (NYSE: VRX) gives back early gains, now flat
... More